Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin
This article was originally published in The Tan Sheet
Executive Summary
Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM
You may also be interested in...
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Reckitt's Lysol Innovation Leads Launches As Acquisition Talk Subsides
Reckitt Benckiser looks to continue feeding organic growth through innovative product launches, as discussion of the company's acquisition search has quieted in recent months
Perrigo Claims Reckitt's Bid To Block Generic Mucinex Is "Baseless"
Reckitt Benckiser's petition seeking to define specific bioequivalence standards for private-label versions of Mucinex OTC cough products, if followed, would push FDA to violate generic drug law, Perrigo argues